AbbVie stock at EUR 263.20, up 1.35% before Xetra
Published on 11/09/2026 at 08:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline Deal Adds Optionality
- AbbVie secured exclusive worldwide rights to develop and sell the investigational inflammatory bowel disease program NXE0033744.
- The agreement provides Nxera Pharma with EUR-equivalent USD 100 million upfront, up to USD 1.37 billion in further milestones and tiered royalties.
- The upfront payment remains subject to customary antitrust clearance, including Hart-Scott-Rodino review.
AbbVie stock traded at EUR 263.20 on Lang & Schwarz at 08:33 CET on Monday, November 9, 2026, 1.35 percent above the Xetra close of Friday, November 6, at EUR 259.70.
Immunology Pipeline Adds Optionality
On Wednesday, November 4, Nxera Pharma said AbbVie had taken exclusive worldwide rights to develop and sell NXE0033744 for inflammatory bowel disease. NovaPharmaNews reported that the program is an investigational oral EP4 receptor agonist.
Nxera is set to receive USD 100 million upfront, up to USD 1.37 billion in additional development and commercial milestones, plus tiered royalties on net sales. The upfront payment remains subject to customary antitrust clearance, including Hart-Scott-Rodino review.
The agreement gives AbbVie another immunology asset, but NXE0033744 is not approved and remains subject to further development and regulatory decisions. A completed Phase 1 program supports the next stage of evaluation, while the milestone structure links much of the potential consideration to future progress.
Investors can follow the real-time quote of AbbVie stock during the European session.
The broader US market backdrop is tracked through the S&P 500.
More news and analyses on AbbVie stock remain available for investors tracking the pipeline and regulatory outlook.
